Early access programs and managed entry agreements for medicines in Italy : results of a Focus Group (Early Access Programs and Managed Entry Agreement).
BACKGROUND: Early access of medicines occurs with an uncertainty in the evidence even higher than the one experienced when price and reimbursement status is negotiated. Our aim is discussing the role of managed entry agreements (MEA) within early access programs (EAP) in Italy.
METHODS: The discussion relied on a Focus Group, participated by twelve experts, including clinicians and representatives of regulatory authorities, regional and local pharmaceutical departments, pharmaceutical companies, and an association advocating for active citizenship.
RESULTS: The Focus Group emphasised that the topic under discussion should be embedded into a more general reform of EAP in Italy. The 648 List mostly includes mature products and indications that are rarely launched into the market afterwards. The 5% Fund is affected by an important administrative burden uncertainty of the timing of reimbursement.
CONCLUSIONS: Starting from the discussion on MEA and EAP, the Focus Group recommended a new legislation better regulating EAP, that early access concerns specific classes of medicines selected on the grounds of the need to guarantee a rapid access and to collect real world data, that early access can be accompanied by outcome-based and population-based MEA, and that MEA are embedded into the subsequent price and reimbursement negotiation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 112(2021), 11 vom: 12. Nov., Seite 749-756 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) |
|---|
| Beteiligte Personen: |
Jommi, Claudio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 19.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/3696.36853 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333205391 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333205391 | ||
| 003 | DE-627 | ||
| 005 | 20231225221156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/3696.36853 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333205391 | ||
| 035 | |a (NLM)34782810 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Jommi, Claudio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early access programs and managed entry agreements for medicines in Italy |b results of a Focus Group (Early Access Programs and Managed Entry Agreement). |
| 246 | 3 | 3 | |a Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Early access of medicines occurs with an uncertainty in the evidence even higher than the one experienced when price and reimbursement status is negotiated. Our aim is discussing the role of managed entry agreements (MEA) within early access programs (EAP) in Italy | ||
| 520 | |a METHODS: The discussion relied on a Focus Group, participated by twelve experts, including clinicians and representatives of regulatory authorities, regional and local pharmaceutical departments, pharmaceutical companies, and an association advocating for active citizenship | ||
| 520 | |a RESULTS: The Focus Group emphasised that the topic under discussion should be embedded into a more general reform of EAP in Italy. The 648 List mostly includes mature products and indications that are rarely launched into the market afterwards. The 5% Fund is affected by an important administrative burden uncertainty of the timing of reimbursement | ||
| 520 | |a CONCLUSIONS: Starting from the discussion on MEA and EAP, the Focus Group recommended a new legislation better regulating EAP, that early access concerns specific classes of medicines selected on the grounds of the need to guarantee a rapid access and to collect real world data, that early access can be accompanied by outcome-based and population-based MEA, and that MEA are embedded into the subsequent price and reimbursement negotiation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Armeni, Patrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Alberti, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Bandello, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Bordonaro, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Caprodossi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Di Maio, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Gaudioso, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliani, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Langella, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Marata, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Patarnello, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Rasi, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Villa, Federico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 112(2021), 11 vom: 12. Nov., Seite 749-756 |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2021 |g number:11 |g day:12 |g month:11 |g pages:749-756 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/3696.36853 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2021 |e 11 |b 12 |c 11 |h 749-756 | ||